BMH Bräutigam advises capiton on series E investment in AlphaPet Ventures and acquisition of Healthfood24 GmbH

BMH BRÄUTIGAM has advised the financial investor capiton AG on the acquisition of a share in AlphaPet Ventures as part of a series E financing round. In this transaction capiton is acquiring 36% of the AlphaPet shares with the capiton V fund, thereby financing the acquisition of the Healthfood24 GmbH by AlphaPet Ventures.

The Munich-based AlphaPet Ventures GmbH is a leading online provider for premium pet food. The Leipzig-based Healthfood24 GmbH stands for species-appropriate pet food of the highest quality and is especially known for its two premium brands Wolfsblut and Wildcat. With this acquisition, AlphaPet Ventures will further expand and strengthen its position as a leading premium supplier of healthy pet food in both Germany and Europe. With 125 employees and nearly triple-digit million sales, the company positions itself as a strong player in the market. The transaction is still subject to approval by the relevant cartel offices.                                                                                                                                                                                                                                                                                                                    Background: BMH BRÄUTIGAM has been advising capiton for over a decade on the acquisition and sale of companies, most recently on the acquisition of the Dec Group.                                                                                                                                                                                                                                                                                                                    Team BMH BRÄUTIGAM: Dr. Patrick Auerbach-Hohl, Dr. Matthias Rüping, Katharina Erbe, Dr. Julian Schroeder (all Venture Capital), Dr. Andrea Reichert-Clauß, Tina Schmidt, Dr. Sylko Winkler (all Private Equity ǀ Corporate/M&A), Janina Erichsen, Raoul Moriz Nissen (beide Venture Capital), Dr. Manuel Holzmann (Private Equity ǀ Corporate/M&A)